(Q34637021)

3 August 2017

1 reference

title

The natural history and antiviral treatment of hepatitis C in haemophilia (English)

1 reference

3 August 2017

1 reference

1 reference

Lee C

1

1 reference

3 August 2017

Dusheiko G

series ordinal

2

1 reference

3 August 2017

publication date

1 May 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

322-329

1 reference

Hepatitis B and hepatitis C co-infection in patients with HIV.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Hepatitis C infection and viremia in Dutch hemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

The natural history of chronic hepatitis C in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

45-year follow-up of hepatitis C virus infection in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Hepatocellular carcinoma in hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Consequences of chronic hepatitis C: a review article for the hematologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Clinical, virological and epidemiological basis for the treatment of chronic non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Guidelines on the diagnosis, management and prevention of hepatitis in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Interferon-alpha therapy for chronic hepatitis C in special patient populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Hepatitis C genotypes in haemophilic patients treated with alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Hepatitis C and haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Interferon therapy for chronic non-A non-B and chronic delta liver disease in haemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Interferon alfa for chronic hepatitis C in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2002.00620.X

10.1046/J.1365-2516.2002.00620.X

21 January 2018

Identifiers

DOI

1 reference

release_4d6e3ywndrfe7fxmy2zsw6qsja

3 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4d6e3ywndrfe7fxmy2zsw6qsja

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference